Dr. Rizk on the Role of Surgery in Nonmetastatic Lung Cancer
Nabil P. Rizk, MD, MS, MPH, discusses the role of anatomic surgical resection in nonmetastatic lung cancer.
Related Articles
Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma
Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.
Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis
Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.
Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification
Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.
Common Medication for Lung Cancer Symptoms Found to Limit Effectiveness of Cancer Treatment
High doses of corticosteroids are likely the most significant factor in why some immunotherapies don’t work.
New Approaches Combat GVHD and Improve Transplantation Outcomes in Hematologic Malignancies
In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.
Tambiciclib Plus Azacitidine and Venetoclax Elicits Robust Antitumor Activity in R/R AML
Tambiciclib plus azacitidine and venetoclax generated favorable ORR, OS, and safety outcomes in patients with relapsed/refractory acute myeloid leukemia.
Early Safety Data Show Tolerability of Apalutamide Plus Carotuximab in Metastatic CRPC
Apalutamide plus carotuximab has been demonstrated to be well tolerated in patients with metastatic castration-resistant prostate cancer
Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab Displays High Response Rate in Unresectable Melanoma
The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.
ELM-2 Data Display Long-Term Efficacy and Safety of Odronextamab in R/R Follicular Lymphoma
Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.
Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer
Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.